Seractide / ACTH 1-39 — adrenal function testing in plain English
7 min read · Uplevel editorial
You've been fatigued for two years. Not tired — fatigued. The kind where waking up doesn't end it, where the second half of every day feels like dragging yourself through something thick, where you've stopped scheduling things in the afternoon because you know you'll be useless. The labs your primary care doctor ran came back "normal." But normal relative to what, and for whom, and measured at what time of day — those questions don't usually get asked. If they do get asked, eventually someone orders an ACTH stimulation test, and what that test measures is more specific and more useful than most fatigue workups. Understanding what it's doing requires understanding the gland it's interrogating.
The adrenal cortex produces cortisol. Not occasionally — continuously, in a tightly regulated diurnal rhythm that rises sharply before waking, peaks in the morning, and falls through the afternoon and evening to a nadir around midnight. Cortisol is not simply a stress hormone, though that's how it's usually described. It's a survival signal. It mobilizes glucose, regulates immune activity, maintains vascular tone, and modulates mood and cognition. The system that governs its production runs from the hypothalamus, which releases corticotropin-releasing hormone (CRH), to the anterior pituitary, which responds with ACTH — adrenocorticotropic hormone — to the adrenal cortex, which responds to ACTH by synthesizing and releasing cortisol. This is the HPA axis, and it's one of the most clinically important regulatory pathways in the body.
Seractide is a synthetic full-length ACTH — the complete 39-amino-acid sequence of endogenous adrenocorticotropic hormone, identical to what the anterior pituitary would normally produce. Administered as an intravenous or intramuscular injection, it bypasses the hypothalamus and pituitary entirely and speaks directly to the adrenal cortex. If the adrenal cortex is functional, it will respond within thirty minutes by producing cortisol. If it doesn't respond, that tells you something specific and important about where in the HPA axis the problem lives.
The ACTH stimulation test works as follows. A baseline cortisol is drawn. Then Seractide — or the more commonly used synthetic ACTH 1-24 fragment, cosyntropin — is injected. Cortisol is measured again at thirty and sixty minutes. An adequate response is typically defined as cortisol rising above 18 to 20 micrograms per deciliter (exact cutoffs vary slightly by assay and laboratory). If cortisol rises adequately, the adrenal cortex is functional: it has intact steroidogenic machinery, it has receptors that respond to ACTH, and it can produce cortisol on demand. If cortisol doesn't rise adequately, the adrenal cortex is not producing an adequate response — and now the question becomes why.
The distinction between primary and secondary adrenal insufficiency is what makes the test diagnostically specific. Primary adrenal insufficiency — Addison's disease — means the adrenal gland itself is damaged or destroyed, most commonly by autoimmune adrenalitis in Western countries, or by tuberculosis, metastatic disease, or hemorrhage in other contexts. In primary adrenal insufficiency, ACTH stimulation produces a flat response because the gland that should be responding has been compromised. The pituitary may be producing normal or elevated ACTH (it's been signaling harder and harder to a gland that can't answer), but the adrenal cortex has no functional reserve left. Secondary adrenal insufficiency is different: the adrenal gland is structurally intact, but it's been chronically understimulated because the pituitary isn't producing adequate ACTH. The most common cause of secondary adrenal insufficiency is exogenous glucocorticoid use — prednisone, dexamethasone, inhaled or topical steroids at sufficient dose and duration — which suppresses the HPA axis through feedback. The pituitary stops making ACTH because the circulating glucocorticoid signal tells it to stop, and over time the adrenal cortex, no longer receiving its ACTH stimulus, loses some of its functional reserve.
In secondary adrenal insufficiency, a standard-dose ACTH stimulation test (250 micrograms of cosyntropin, the typical clinical dose) may give a normal-appearing response, because even a chronically understimulated adrenal gland retains some capacity to respond acutely to a large exogenous ACTH stimulus. This is one of the test's important limitations. A low-dose ACTH stimulation test — using 1 microgram rather than 250 micrograms — is more sensitive for detecting secondary insufficiency because the smaller stimulus better mimics physiological ACTH levels, and a gland that's been understimulated may not respond even to a lower but more physiological challenge. The choice between standard and low-dose tests is a clinical one that depends on what you're trying to detect.
Seractide specifically — the full 39-amino-acid ACTH — carries an additional property worth noting. The first 24 amino acids of ACTH are sufficient for adrenocortical stimulation (which is why cosyntropin, ACTH 1-24, works as the standard test reagent), but the remaining amino acids, positions 25-39, influence ACTH binding to melanocortin receptors and affect the melanogenic properties of the molecule. Seractide as a full-length molecule more closely mimics endogenous ACTH in terms of its full receptor interaction profile, though in clinical practice the diagnostic utility of cosyntropin is well-established and it's the more widely used reagent. Seractide is used in some therapeutic contexts as well — historically in infantile spasms, a severe epileptic syndrome of infancy, where ACTH therapy reduces seizure burden through mechanisms that are still not fully characterized but appear to involve central rather than purely adrenal effects.
The ACTH stimulation test matters in the chronic fatigue and HPA-dysfunction conversation because it answers a specific question with some precision. People who describe what sounds like HPA-axis dysfunction — fatigue that worsens through the day, difficulty tolerating physiological stress, low energy despite adequate sleep, mood instability correlated with meals and activity — often present with a workup that checks thyroid and basic metabolic markers but doesn't interrogate adrenal reserve directly. If morning cortisol comes back borderline low, or if the clinical picture is strongly suggestive, an ACTH stimulation test is the appropriate next step because it distinguishes "your adrenal cortex doesn't respond normally" from "your cortisol happens to be low at this particular morning draw."
The limits of the test in subclinical contexts are worth being honest about. A normal ACTH stimulation test doesn't mean your HPA axis is functioning optimally — it means your adrenal cortex has adequate reserve to respond to a pharmacological ACTH stimulus. It doesn't tell you whether your diurnal cortisol pattern is appropriate, whether your cortisol response to real-world stressors is proportionate, or whether subtle dysregulation in the upstream HPA signaling is contributing to how you feel. Those questions require different tools: 24-hour urinary cortisol, midnight salivary cortisol, salivary cortisol awakening response, serial sampling. The ACTH stimulation test is specific and valuable for what it tests, which is adrenocortical reserve. It wasn't designed to be an exhaustive map of the HPA system.
Tertiary adrenal insufficiency deserves a brief mention because it's increasingly common and often goes unrecognized. Prolonged exogenous glucocorticoid use — even inhaled corticosteroids at moderate doses over years, or repeated short courses of oral prednisone — can suppress the hypothalamus, reducing CRH output, which reduces ACTH output, which allows the adrenal cortex to atrophy through lack of stimulation. This isn't Addison's, and it isn't classic secondary insufficiency from pituitary disease. It's HPA suppression from above — from the hypothalamus — and it can be subtle and slow to reverse after steroid discontinuation. The ACTH stimulation test in tertiary suppression may show a delayed or blunted adrenal response if the adrenal has been genuinely understimulated long enough to lose reserve, or it may appear normal if the suppression is primarily at the hypothalamic level and the adrenal cortex is still structurally intact.
For the clinician evaluating someone with fatigue, low blood pressure, salt craving, difficulty recovering from illness, and a sense that stress hits harder than it should — all features that raise HPA-axis questions — the ACTH stimulation test is a precise and useful instrument. It rules in or rules out the pathological end of the spectrum. What it leaves open is the substantial clinical territory between "your adrenal cortex is clearly insufficient" and "your adrenal cortex is clearly fine" — the zone of subclinical dysregulation where many people are actually living. That zone is real. The test isn't designed to map it, and it shouldn't be asked to.
Understanding what Seractide tests — and what it can't — is part of understanding adrenal biology honestly. The HPA axis is not a binary system. Adequate adrenocortical reserve under pharmacological challenge is not the same as a robust cortisol awakening response or a well-calibrated diurnal rhythm. Those are different questions requiring different tools, evaluated by a clinician who understands the difference between ruling out Addison's and actually characterizing the full texture of someone's stress-response physiology.
Frequently asked